Oracle’s Hardware Business Predicted to Rebound and 4 Stock Analyses Sparking Chatter
Orexigen Therapeutics, Inc. (NASDAQ:OREX): Current Price: $5.75
Takeda, which has agreed to market Orexigen’s anti-obesity drug, gained FDA approval for its type 2 diabetes treatment, influencing JMP Securities to view the development as positive for Orexigen. The firm has stated that it believe that the approval makes Takeda more likely to dedicate resources to cardiometabolic diseases in general. JMP Securities keeps its Outperform rating on the stock.
Wabash National Corp. (NYSE:WNC): Current Price: $10.56
FBR Capital raised its price target for Wabash after ACT Research issued a stronger than expected December 2012 U.S. Trailers report. The firm says the report strengthens its bullish outlook Wabash and reiterates an Outperform rating on the name.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
Oracle Corp. (NASDAQ:ORCL): Current Price: $35.50
Pacific Crest decided to raise its target on Oracle due to the firm’s expectations that the company’s hardware business will see a rebound during 2013. The firm predicts that Oracle faces less competition than its large cap peers and it keeps its Outperform rating on the stock.
Susquehanna Bancshares, Inc. (NASDAQ:SUSQ): Current Price: $11.55
Susquehanna reported Q4 results that are viewed by BB&T as solid and the firm is convinced that the bank is making progress toward being seen as a a top tier operator. The firm thinks that the bank is in a great position for a solid 2013 and it keeps its Buy rating on the stock.
EMC Corporation (NYSE:EMC): Current Price: $25.02
Brean Capital still likes EMC due to reduced investor sentiment, solid channel checks, and new product cycles. Shares keep a Buy rating.